[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568351":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":30,"locations":39,"responsibleParty":57,"collaborators":34,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":34,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":34,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":42,"whyStopped":34,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CD70-targeted immunoPET imaging","EXPERIMENTAL","Enrolled patients will undergo a CD70-targeted immunoPET\u002FCT scanning.",[13],"Drug: [18F]RCCB6",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","[18F]RCCB6","Enrolled patients will receive 0.05-0.1mCi\u002Fkg of \\[18F\\]RCCB6. ImmunoPET\u002FCT imaging will be acquired 1 hour after \\[18F\\]RCCB6 injection.",[9],[21],"[18F]F-RESCA-RCCB6",[23,27],{"name":24,"affiliation":25,"role":26},"Wei Zhai, Ph.D. & M.D.","Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","STUDY_CHAIR",{"name":28,"affiliation":25,"role":29},"Weijun Wei, Ph.D. & M.D.","PRINCIPAL_INVESTIGATOR",[31,36],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":35},"CONTACT","15000083153",null,"wwei@shsmu.edu.cn",{"name":24,"role":32,"phone":37,"phoneExt":34,"email":38},"18701771959","jacky_zw2002@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","Shanghai Municipality","200127","China","CN",{"type":49,"coordinates":50},"Point",[51,52],121.45806,31.22222,{"lat":52,"lon":51},[55,56],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":35},{"name":24,"role":32,"phone":37,"phoneExt":34,"email":38},{"type":58,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100568351","phase-2-cd70-targeted-immunopet-imaging-of-kidney-cancer-100568351",false,"NCT06680089","CD70-targeted immunoPET Imaging of Kidney Cancer","A Study of the Clinical Application of [18F]RCCB6 PET\u002F CT Imaging in the Diagnosis of Kidney Cancer","Inclusion Criteria:\n\n1. Aged 18-80 year-old and of either sex；\n2. Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","ALL","18 Years","80 Years",{"count":70,"type":71},300,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","The aim of this study is to establish and optimize the \\[18F\\]RCCB6 PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.",[77,78,79,80],"Urologic Neoplasms","Urogenital Neoplasms","Kidney Neoplasms","Neoplasms",[82,83,84,85],"The cluster of differentiation (CD70)","Kidney tumor","Clear cell renal cell carcinoma","ImmunoPET","2025-12-25",{"date":88,"type":89},"2025-12-31","ACTUAL",{"date":91,"type":89},"2024-11-27",{"date":93,"type":71},"2027-11",{"name":5,"class":6},1]